News and Media

For press releases:

2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999

Receive E-mail alerts

Subscribe to RSS feeds

December 20, 2007

MedImmune Expands Scientific and Engineering Leadership

December 19, 2007

Infinity and Medimmune Initiate Phase 2 Trial of IPI-504 to Assess the Hsp90 Inhibitor’s Potential Anti-Tumor Activity in Patients with Advanced Non-Small Cell Lung Cancer

December 10, 2007

Micromet and MedImmune Present New Clinical Data for MT103 at the American Society of Hematology Annual Meeting Suggesting Potent Single-Agent Activity in Patients with Relapsed Mantle Cell and Follicular Lymphoma

December 7, 2007

AstraZeneca Presents its Global Biologics Organisation, MedImmune, at 2007 Analyst and Investor R&D Day

November 29, 2007

Micromet and MedImmune to Present New Clinical Data for Anti-CD19 BiTE® Antibody at American Society of Hematology Annual Meeting Showing Objective Clinical Responses in Relapsed Non-Hodgkin’s Lymphoma Patients

November 26, 2007

MedImmune Initiates First Clinical Trial of Monoclonal Antibody Targeting GM-CSFR in Patients with Rheumatoid Arthritis

November 14, 2007

The New England Journal of Medicine Publishes First Clinical Results for MedImmune's Chitinase-like Protein YKL-40 in Patients With Asthma

November 13, 2007

Infinity and MedImmune Initiate Phase 2 Clinical Trial of IPI-504, a Novel HSP90 Inhibitor, in Patients with Advanced Hormone-Refractory Prostate Cancer

November 8, 2007

MedImmune Presents Data from Its Advancing Inflammatory Disease Portfolio at 71st Annual Meeting of The American College of Rheumatology

November 5, 2007

MedImmune Announces Seven Key Promotions and New Hires

October 29, 2007

PHOTO ADVISORY -- AstraZeneca Bolsters Its Worldwide Biologics Division Through Integration of Cambridge Antibody Technology Into MedImmune

October 29, 2007

AstraZeneca Bolsters Its Worldwide Biologics Division Through Integration of Cambridge Antibody Technology Into MedImmune

October 29, 2007

MedImmune Presents New Pharmaco-Economic Data at American Academy of Pediatrics Regarding Infants at High Risk for RSV

October 26, 2007

MedImmune to Present RSV Surveillance and Cost-Effectiveness Data at American Academy of Pediatrics National Conference & Exhibition

October 25, 2007

Infinity and MedImmune Present Preliminary Phase 1 Data Demonstrating Biological Activity of IPI-504, a Novel HSP90 Inhibitor, in Advanced Non-Small Cell Lung Cancer

October 24, 2007

MedImmune Recognized by Local Volunteer Organization for Its Employees' Exceptional Commitment to Community Service within Montgomery County

October 23, 2007

Infinity and MedImmune Announce Issuance of U.S. Patent for Proprietary Heat Shock Protein 90 Inhibitors

October 15, 2007

MedImmune and Crucell Announce Collaboration to Develop New Antibodies for the Treatment and Prevention of Hospital-Acquired Bacterial Infection

October 9, 2007

Data from MedImmune Infectious Disease Clinical Programs Presented at European Society for Paediatric Research Annual Meeting

October 4, 2007

MedImmune Announces Phase 2 Safety Data for Anti-RSV Antibody and National RSV Surveillance Results

September 24, 2007

MedImmune Licenses Reverse Genetics Technology to GlaxoSmithKline for Use in Influenza Vaccine Development and Production

September 19, 2007

FDA Approves Expanded Label for FluMist(R) to Include Children Two to Five Years of Age

September 17, 2007

Infinity and MedImmune Receive Orphan Drug Designation for IPI-504 for Treatment of Gastroinstestinal Stromal Tumors

September 7, 2007

MedImmune Resolves FDA Observations Regarding Manufacturing Process for FluMist(R)

August 23, 2007

MedImmune Celebrates Opening of New Pilot Lab at Gaithersburg Headquarters

August 23, 2007

MedImmune's Motavizumab Reduced RSV Hospitalizations by 83 Percent Among High-Risk Native American, Full-Term Infants in Placebo-Controlled Phase 3 study

August 23, 2007

MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production

August 1, 2007

MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma

July 23, 2007

MedImmune Announces Interim Phase 1 Study Results for Potential Asthma Therapy

July 19, 2007

MedImmune Advances Potential Treatment for Patients With Lupus

July 16, 2007

RSV Drug Starts Phase Ia Clinical Trials

July 3, 2007

MedImmune Begins Dosing Children Six Months to 24 Months of Age in Phase 1 Study of Vaccine to Help Prevent Two of the Most Common Viral Causes of Childhood Respiratory Illness

June 29, 2007

New Study in Journal of Pediatrics Suggests Synagis(R) (Palivizumab) May Reduce Subsequent Recurrent Wheezing in Preterm Infants

June 18, 2007

MedImmune, Inc. Announces Make-Whole Fundamental Change Relating to its 1.375% Convertible Senior Notes Due 2011 and 1.625% Convertible Senior Notes Due 2013

June 14, 2007

Medimmune Is Awarded Contract By U.S. Department Of Health and Human Services to Retrofit Manufacturing Facilities For Production of Pandemic Influenza Vaccines

June 12, 2007

MedImmune Wins Stevie(R) Award at 5th Annual American Business Awards(SM)

May 31, 2007

Infinity and MedImmune Announce Updated Data On Ipi-504 to be Presented At ASCO

May 25, 2007

MedImmune Receives Correspondence From FDA Regarding FluMist(R)

May 24, 2007

MedImmune Highlights Advances in Inflammatory Disease Pipeline With Series of Data Presentations

May 16, 2007

FDA Advisory Committee Recommends Expanded Use of FluMist(R)

May 8, 2007

Data Show FluMist(R) May Reduce Seasonal Influenza Burden Among Children in School, Daycare Settings

May 8, 2007

MedImmune Announces Positive Clinical Results at PAS Annual Meeting From Large Prospective Trial in Prevention of Serious RSV Disease

May 7, 2007

MedImmune Provides Fellowship Grants To Six Pediatric Respiratory Researchers

May 7, 2007

MedImmune and Pediatric Infectious Diseases Society Present 2007 Career Development Award and Viral Respiratory Disease Fellowship

May 2, 2007

MedImmune, Inc. Announces Convertibility of 1.375% Convertible Senior Notes Due 2011 and 1.625% Convertible Senior Notes Due 2013

May 2, 2007

Pediatric Academic Societies' Annual Meeting to Feature Data Presentations Related to MedImmune Clinical Programs in Influenza, RSV and hMPV

April 30, 2007

MedImmune Reports Financial Results for 2007 First Quarter

April 30, 2007

MedImmune and Micromet Publish Data on Novel Anti-Cancer BiTE® Molecule

April 23, 2007

AstraZeneca to acquire MedImmune for $58 per share in a fully recommended, all-cash transaction with a total enterprise value of $15.2 billion

April 18, 2007

MedImmune Publishes New Data in Nature Immunology Demonstrating The Role HMGB1 May Play in Systemic Autoimmune Diseases

April 18, 2007

Micromet and MedImmune Present Data From Preclinical Study of New BiTE(R) Molecule Targeting CEA

April 12, 2007

MedImmune Explores Strategic Alternatives

April 10, 2007

Infinity and MedImmune to Present Preclinical Data From Study of Oral Formulation of IPI-504 At AACR

April 9, 2007

MedImmune Announces Preliminary Results for 2007 First Quarter

April 2, 2007

MedImmune Promotes Three Leaders in Key Scientific & Medical Roles

April 2, 2007

MedImmune Announces Addition of Robert H. Hotz To Board of Directors

March 29, 2007

MedImmune Licenses Reverse Genetics Technology to sanofi pasteur for Use in Influenza Vaccine Production

March 23, 2007

MedImmune Expands Anti-Interferon-Alpha Program by Initiating Phase 1 Trial in Patients With Psoriasis

March 21, 2007

Research Results on FluMist(R) Presented at National Association of Pediatric Nurse Practitioners Conference

March 16, 2007

MedImmune Leases Human Genome Sciences Facility to Expand Cell Culture Influenza Vaccine Manufacturing Capabilities

March 12, 2007

MedImmune to Present at the Tenth Annual Lehman Brothers Global Healthcare Conference

March 6, 2007

MedImmune to Present at the Cowen & Co. 27th Annual Health Care Conference

February 20, 2007

MedImmune Further Expands its Commercial Organization Expertise With Appointment of Two Additional Vice Presidents

February 14, 2007

Study Published in The New England Journal of Medicine: 55 Percent Fewer Cases of Flu in Young Children Vaccinated With FluMist(R) Vs. Flu Shot

February 14, 2007

Infinity and MedImmune Initiate Phase I/II Clinical Trial of IPI-504 for Patients With Non-Small Cell Lung Cancer

February 7, 2007

MedImmune Reports Financial Results For 2006

January 10, 2007

MedImmune Announces District Court's Rejection of Sun Pharmaceutical's Motion to End Litigation Regarding Generic Amifostine

January 9, 2007

MedImmune Issues Statement Regarding U.S. Supreme Court Decision

January 8, 2007

FDA Approves MedImmune's Refrigerated Formulation of FluMist(R)